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ABSTRACT 
Objective: The objective of this research was to isolate and identify any potential synthetic cannabinoids disguised in the commercially available 
claimed-to-be herbal scent, known as “Funky Green Stuff™”. 
Methods: Potential synthetic cannabinoids were extracted via percolating the content of the commercial herbal scent bag “Funky Green StuffTM
Results: Chromatographic purification afforded 372 mg (5.2% w/w enrichment ratio) of pure needle crystals. Spectral analyses revealed the 
identity of the isolated compound as the synthetic cannabinoid AB-FUBINACA, confirming the assumption that a synthetic cannabinoid was 
disguised as an herbal scent product.  
” in 
methanol. Column chromatographic isolation afforded one main pure compound. Different spectral analyses established the identity of the isolated 
compound. 
Conclusion: Several scent herbal products, also known as “spice”, are used to disguise synthetic cannabinoids. Their detection proved to be 
troublesome since authentic standards are not yet available. The synthetic cannabinoid, AB-FUBINACA, was isolated from one of these products, and 
its identity was established based on its spectral data. 
Keywords: AB-FUBINACA, Synthetic cannabinoids, Spice, Funky Green Stuff, Herbal scent, Spectral analyses. 
 
INTRODUCTION 
The term designer drug refers to those drugs synthesized from 
substances that have been subjected to legal controls. However, 
designer drugs are not subject to the same legal restrictions as their 
precursors [1]. Moreover, designer drugs are legal to use, possess, 
and distribute with the condition that they must be marketed for 
purposes other than human consumption. As a result, users often 
provide little information regarding potential adverse side effects 
and drug interactions if ingested [2]. 
While designer drugs comprise a huge number of products, herbal 
products containing synthetic cannabinoids, more commonly called 
spice products, have recently become the subject of intense media 
attention and coverage. Herbal products containing synthetic 
cannabinoids are often advertised as an “incense blend” and are 
generally labeled “not for human consumption” by their 
manufactures [3]. 
Synthetic cannabinoids, also called cannabimimetics, are compounds 
that affect the endo cannabinoid system mainly through binding 
with the CB1 and CB2 receptors [4, 5]. Synthetic cannabinoids are 
chemically unrelated compounds that function similarly to Δ9-THC 
[6]. They produce a number of psychoactive effects including 
euphoria, sensory perception enhancements, severe memory 
impairments, and hallucinations [7]. 
The names of these compounds reflect mainly their academic or 
pharmaceutical origin and, sometimes, their chemistry. For example, 
JWH-compounds, such as JWH-018 and JWH-073 are the initials of 
the chemistry professor John W. Huffman who first synthesized 
these compounds. AM compounds, such as AM-630, refer to 
Professor Alexandros Makriyannis, while HU, in HU-210, refers to 
the Hebrew University [8]. 
Products of these compounds first appeared in 2004 in Europe 
mixed with herbal products and were advertised as natural herbal 
incense. Examples of these products are “Spice Diamond”, “Spike”, 
and “Funky Green Stuff” among others. However, it was found that 
these products are produced by mixing synthetic cannabinoids with 
dried herbs or by spraying them dissolved in organic solvents [9]. 
These products are so popular because they offer an alternative to 
natural cannabis, in addition to the fact that there are currently no 
accurate, reliable screening tools to detect them in the human body 
[6]. Also, these products are consumed by those who want a legal 
alternative to illegal drugs and experimental drug users, especially 
teenagers and young people between the ages of 25 and 40 [6]. 
These compounds typical doses are usually less than 1 mg due to their 
much higher potency than Δ9-THC [6]. Packages of synthetic 
cannabinoids products were initially sold via internet shops but are now 
being sold in head shops, local tobacco shops, and gas stations [10]. 
In December 2008, forensic chemical analysis done in Germany and 
Austria revealed that the psychoactive properties of herbal mixtures, 
such as ‘Spice’, were the direct result of added synthetic 
cannabinoids [3].  
Days before, the presence of an aminoalkylindole called JWH-018 
was identified in several samples of spice products [11]. Subsequent 
analyses of spice products in laboratories across Europe, including 
Finland, France, Hungary, Poland, and the United Kingdom, also 
confirmed the presence of synthetic cannabinoids [6]. 
Little is known about the metabolism and toxicity of synthetic 
cannabinoids, as these products were only tested in the laboratory 
[3]. However, there are reasons for concerns that these products 
may cause more harm than natural cannabis. One reason is their 
high affinity and potency, as some synthetic cannabinoids, e. g., HU-
210, are reported to have 4-5 times the binding affinity for CB1 
receptor of Δ9
Synthetic cannabinoids are classified according to their chemical 
structures (fig. 1). According to the United Nations Office on Drugs 
and Crime (UNDOC) [14], these compounds are classified into: 
classical cannabinoids, non-classical cannabinoids (e. g., 
cyclohexylphenols, 3-arylcyclohexanols), hybrid cannabinoids, 
aminoalkylindoles (e. g., naphthoylindoles, phenylacetylindoles, 
benzoyl indoles, and napthylmethylindoles), and others (e. g., 
endocannabinoids and their synthetic analogues, diarylpyrazoles, 
derivatives of naphthalene-1-yl, and methanone). 
-THC [12, 13]. Even more worrying, based on its 
structure, it is presumed that the synthetic cannabinoid JWH-18 may 
possess carcinogenic properties [12]. 
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3) Aminoalkylindoles, e. g., naphthoylindoles, phenylacetylindoles and benzoylindoles: 
Fig. 1: Some synthetic cannabinoids 
 
The information on the pharmacokinetics and pharmacodynamics of 
synthetic cannabinoids is scarce compared to natural cannabis. A 
study done by Teske, et al. showed that the maximum 
concentrations of JWH-018 were found 5 min after smoking the 
incense ‘smoke’. These maximum concentrations lasted for 3 h, 
while the parent compound was still detectable until 48 h after 
administration [15]. In chronic users, large quantities of these 
lipophilic compounds are likely to accumulate in fat-containing 
compartments after absorption.  
Metabolism studies on these compounds are not easily conducted, due to 
the ethical concerns regarding administering such products in humans 
[8]. Thus, studies available on the metabolism of synthetic cannabinoids 
are either based on human liver microsomes experiments or human 
urine samples analysis from caught users or conducted self-experiments, 
with aminoalkylindoles being the most studied [16–18]. 
What makes the control of spice products so difficult, according to 
UNODC, is that despite the proactive approach lawmakers 
worldwide are employing, the producers of these substances seem 
to be aware of these efforts and, thus, respond so quickly to changes 
in legislation by making small modifications to the new product 
launched without affecting its cannabis-like effects [14]. For 
example, after the prohibition of the use and distribution of JWH-
018-containing products in Germany, a second generation of herbal 
products containing the synthetic cannabinoid JWH-073 as an 
alternative began to fill the market just a month later [19]. In 
addition, none of the synthetic cannabinoids are internationally 
controlled under the United Nations drug control convention. Each 
country has its own regulations and develops their own schedules in 
order to control these products. 
The most important barrier affecting the control of the distribution 
of these products is the role that the internet plays. The internet has 
already become an unregulated source of drugs, both controlled and 
uncontrolled, which has immense legal and public health 
implications. Online vendors of designer drugs can easily evade the 
laws of other countries, rendering efforts to regulate such 
substances ineffective [20]. In Kuwait, a joint committee was formed 
between the Ministries of Health, Interior, Justice, and Commerce 
and Industry and the General Administration of Customs and a 
resolution came out on March 15, 2015 stating that the importation 
of any of the products marketed under the name “Spice” or Bath 
Salt” is banned. However, more work should be done to construct 
the needed tables and more legal work is required as well to 
schedule these compounds. 
The abuse of cannabimimetics, including synthetic cannabinoids, 
cannot be detected using methods that are used for detecting 
cannabis abuse. Reference material for most synthetic cannabinoids 
is currently unavailable due to the immense variety of these 
products in the market. Without reference material, reliable 
identification and quantification of synthetic cannabinoids in herbal 
products would be difficult. 
MATERIALS AND METHODS 
General experimental procedure 
Melting points were determined in open capillary tubes using a 
Mettler 9100 electrothermal melting point apparatus and were 
uncorrected. IR spectra were recorded using JASCO FTIR-4100 
spectrophotometer. UV spectra were measured in methanol using UV-
visible dual-beam spectrophotometer. The 1H and 13C NMR spectra 
were obtained on a Bruker Avance II 600 MHz spectrometer operating 
at 600 and 150 MHz, respectively. 19F NMR spectra were obtained on a 
Bruker DPX 400 MHz spectrometer operating at 376.46 MHz. 1H, 13C, 
and 19F NMR spectra were recorded in CDCl3, and the chemical shift 
values were expressed in δ (ppm) relative to the internal standard 
tetramethylsilane (1H, 13C) and trifluorotoluene (19F). For the 13
NMR and Low Resolution Mass Spectrometry (LRMS) spectral 
analyses were performed at the Science General Facilities, Faculty of 
Science, Kuwait University. Additionally, LC-MS analysis was done on a 
Thermo Scientific LCQ fleet mass spectrometer connected to Thermo 
Scientific Surveyor Liquid Chromatography Plus system via electro 
spray ionization interface (ESI) at the Faculty of Pharmacy, Kuwait 
University. UV and IR analyses were done at the Department of 
Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University. 
Column chromatography was done using flash silica gel 60 (0.04-0.063 
mm/230-400 mesh, ASTM, Merck). Thin Layer Chromatography (TLC) 
analyses were performed on 5x10 cm, 250 microns, pre-coated glass 
plates, with UV
C NMR 
spectra, spectral editing was determined by DEPT. 2D NMR data were 
obtained using the standard pulse sequence of the Bruker 600 for 
COSY, HSQC, and HMBC. Low resolution Electron Ionization Mass 
Spectrometry (EIMS) were obtained using a double-focusing magnetic 
sector mass spectrometer (GS-MS DFS/Thermo).  
254 indicator (Anal Tech). The following solvent systems 
were used for the development of TLC: toluene: methanol: diethyl 
amine; 8: 1.5: 0.5, and chloroform: methanol; 9.7: 0.3. TLC plates were 
visualized after development via exposure to short (λmax 254 nm) and 
long wavelength (λmax
Materials 
 366 nm) UV light (CAMAG), then spraying with 
p-anisaldehyde/sulfuric acid spray reagent and Dragendorff’s spray 
reagent. All solvents used were of general purpose grade. 
One pack of “Funky Green Stuff TM” was provided by the General 
Administration of Criminal Evidences, Ministry of an Interior, 
Orabi et al. 
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Kuwait. 7.16 g of the content were used for analysis. Physical 
examination of the material inside the pack revealed a ground dried 
green plant material. Microscopic examination of some of this 
material revealed tiny colorless crystals adsorbed on the plant 
material suggesting the presence of a synthetic compound(s). 
Extraction 
7.16 g of plant material were percolated in 190 ml methanol 
overnight. The plant material was filtered off and steeped again in 
fresh methanol (190 ml). The process was repeated for a third time 
and the combined methanol layers were evaporated in vacuo at 38˚C 
till dryness to afford 1.68 g greenish residue. 
Thin layer chromatographic analysis 
Several TLC trials were done on the extract to determine the best 
solvent system to be used to isolate the main compound(s). Toluene: 
methanol: diethyl amine; 8: 1.5: 0.5, were found to give a reasonable 
isolation of the main compound on the TLC plate. This compound 
contains a nitrogen atom as shown by its intense orange color after 
spraying with Dragendorff’s spray reagent. 
Isolation and purification of the potential synthetic 
cannabinoid 
The obtained residue (1.68 g) was purified on a flash silica gel 
column (160 g, 4.5 cm x 31 cm) and eluted with toluene: methanol: 
diethyl amine; 8.8: 0.7: 0.5. 50-ml Fractions were collected. Similar 
fractions, based on TLC analysis, were pooled together. Fractions 5-7 
were pooled together and evaporated to dryness to afford 412 mg 
semi-pure slightly greenish needle-like crystals. 
These crystals were further purified over a flash silica gel column 
(60 g, 2.5 cm x 19 cm) and eluted with chloroform: methanol; 9.7: 
0.3. Fractions 17-24 showed one main UV-active compound. These 
fractions were pooled together and evaporated to dryness, followed 
by crystallization from methanol to give 372 mg (5.2% w/w 
enrichment ratio) of colorless needles, called RA-2. 
RA-2: colorless needles (acetone-petroleum ether): mp 163-165 ˚C; 
UV (MeOH) λmax (log ε) 220 (3.71), 301 (3.35) nm; IR (neat) vmax 
3372, 3295, 3187, 1664, and 1639 cm-1; 1H NMR (CDCl3, 600 MHz) 
see table 1; 13C NMR (CDCl3, 150 MHz) see table 1; 19F NMR (CDCl3, 
376.46 MHz); EIMS (70 eV) m/z 324.3 [M-CONH2]+
 
. 
Table 1: 1H and 13C NMR Data (CDCl3
# 
) for RA-2 
δc δ, multiplicity H, multiplicity (J in Hz) 
3 137.5, C --- 
4 123.5, C --- 
5 123.0, C 8.34, ddd (7.2, 0.9, 1.2) 
6 109.6, CH 7.28, ddd (7.2, 7.2, 1.2) 
7 127.2, CH 7.38, ddd (7.2, 7.2, 1.2) 
8 122.9, C 7.33, ddd (7.2, 1.2, 0.9) 
9 141.1, C --- 
10 162.9, C --- 
11 53.1, CH 5.59, s 2 
1` 131.7, C --- 
2` 129.1, CH 7.19, dd (9.0, 3.0)
3` 
a 
115.8, CH 7.0, dd (9.0, 2.4)
4` 
b 
161.9, C --- 
5` 116.0, CH 7.0, dd (7.5, 1.8)
6` 
b 
129.2, CH 7.21, dd (7.5, 3.0)
1`` 
a 
173.3, C --- 
2`` 58.1, CH 4.54, dd (8.4, 6.6) 
3`` 30.5, CH 2.37, ds (6.6, 5.4) 
4`` 18.2, CH 1.08, d (5.4)3 
5`` 
c 
19.5, CH 1.09, d (4.8)3 
10-NH 
c 
--- 7.52, d (9.0) 
1``-NH --- 5.53, s 
1``-NH --- 6.19, s 
a,b,c
 
 Protons within the same column are interchangeable 
RESULTS AND DISCUSSION 
The content of “Funky Green StuffTM
RA-2 was isolated as colorless needles. Its molecular formula was 
determined as C
” packet was percolated 
repeatedly in methanol at room temperature. The combined extracts 
were evaporated in vacuo till dryness. TLC analysis revealed that the 
extract contains one main UV-active, N-containing compound, which 
is separable by a combination of toluene, methanol, and diethyl 
amine. Flash chromatography over silica gel yielded a semi pure 
compound. Further chromatographic purification and crystallization 
afforded 372 mg of RA-2 as colorless long needle crystals. 
20H21O2N4F on the basis of the ion peak at m/z 
324.1 [M-CONH2]+and NMR data. ESI mass spectrum showed the 
molecular ion peak at m/z 368.93. On the other hand, IR spectrum 
showed absorption bands for an amino group(s) (3372, 3295, and 
3187; weak absorption bands) and amide carbonyl group(s) (1664 
and 1639; strong absorption bands). 13C NMR showed 20 resonances 
distributed as two quartets (q, CH3), one triplet (t, CH2), 10 doublets 
(d, CH), and 7 singlets (s, C). Three carbons resonated in the 
aliphatic region, and two in the oxygenated/nitrogenated carbon 
region; C-11 resonated at δC 53.1 as t, while C-2`` resonated at δC 
The two methyl groups resonated at δ
58.1 as d. Other carbons resonated in the olefinic/aromatic region. 
C 18.2 and 19.5. From the 
HSQC, those two carbons showed cross contours with 
protonsresonated at δH 1.08 and 1.09, respectively. Both resonances 
appeared as a doublet and integrated for 3 protons each. They were 
assigned to methyl 4`` and 5``. From the COSY spectrum, those 
methyl groups coupled to a common proton (δH 2.37, ds (6.6, 5.4), H-
3``). This proton, in turn, showed coupling in the COSY spectrum 
with another proton (δH 4.54, dd (8.4, 6.6), H-2``). H-2`` showed 
more coupling with an exchangeable proton resonated at δH 7.52 as 
a d with a coupling constant of 9.0 Hz. This proton was assigned to 
the NH on C-10. Moreover, H-2`` showed a cross peak in the HSQC 
spectrum with a doublet carbon resonated at δC 
As mentioned before, the IR spectrum suggested the presence of one 
or more amide carbonyl groups. NH-10 was assigned to one of those. 
From the 
58.1, and hence 
assigned as C-2``. 
1Hand HSQC spectra, two more exchangeable protons were 
assigned to the NH2 on C-1``. These protons resonated as a singlet 
each at δH 5.53 and 6.19. 13C NMR spectrum suggested the presence 
of two amide carbonyl carbons resonated at δC 162.9 and 173.3 and 
was assigned C-10 and C-1``, respectively. The abovementioned NMR 
Orabi et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 10, 111-115 
 
114 
data constituted a solid body of evidence that unambiguously 
supported the presence of a particular side chain (shown below) not 













Other NMR data supported the presence of benzylated indazole 
nucleus. The presence of a sharp signal resonating at δH 5.59 and 
integrated for two protons indicated the presence of a freely rotating 
isolated methylene group. From the HSQC, these protons, H2-11, 
showed a correlation with a triplet carbon resonated at δC 53.1 and 
were assigned to C-11. Confirming this conclusion, the HMBC 
spectra showed a correlation between these protons and the 
aromatic carbons resonating at δC 131.7; C-1`, 129.1; C-2`, and 
129.2; C-6`. From the 1H NMR and COSY spectra, this aromatic ring 
was shown to be para-disubstituted benzene ring, more correctly 
benzyl ring. Other carbons of this system were assigned at δC 115.8, 
C-3`, 161.9, C-4`, and 116.0, C-5`. Other substituent of this ring were 
determined to be 19F from the 19F NMR spectrum, which shows a 
resonance at δF-113.9. Other aromatic carbons assignments were 
done unambiguously from the HSQC and HMBC spectra. These 
carbons were shown to be of an indazole ring system. Complete 1H 
and 13
Therefore, the identity of this compound was revealed to be N-(1-
amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-
3-carboxamide (abbreviated for short AB-FUBINACA). Its structure 
is shown below.  
























RA-2 (AB-FUBINACA)  
AB-FUBINACA is a semi-synthetic cannabinoid that is relatively 
newly introduced to the market. It was first synthesized in 2009 by 
Pfizer as a potent CB1
Similar to Δ
 receptor modulator for potential therapeutic 
use as an analgesic, but was never pursued for human use and was 
identified in 2012 along with a closely related compound, AB-
PINACA, in illegal herbal products in Japan [21]. 
9-THC and other cannabinoids, AB-FUBINACA exhibits its 
effects through the full agonism of the CB1 and CB2 receptors, 
having more selectivity for CB2. It possesses a 10-fold greater 
affinity for the CB1
AB-FUBINACA is a relatively new substance and was not formally 
studied; hence, there is a very little data available about its toxicity 
or addiction potential. Informal experiments have shown that 
overdose will cause side effects including heart palpitations, vertigo 
and sedation at much lower doses than toxic ones, usually causing 
the user to fall asleep. In January 2014, the United States has placed 
AB-FUBINACA into Schedule I controlled substances [22]. Recent 
literature search revealed that there are no previous reports of AB-
FUBINACA detection in “Funky Green Stuff™”. 
 receptor than that of JWH-018 [21]. 
Products of AB-FUBINACA are usually smoked in doses ranging from 
less than 1 mg to more than 5 mg. The onset of the psychoactive 
effects of this compound usually begins 20 min after consumption 
and last 1 to 2 h, with the peak effect at 30 to 60 min after 
consumption. 
ADB-FUBINACA, a similar compound to AB-FUBINACA, contains a tert-
butyl group instead of the isopropyl group. AB-PINACA is another 
closely related compound but contains a pentyl side chain attached to 
the indazole ring system instead of the 4-fluorobenzene ring. 
CONCLUSION 
The synthetic cannabinoid, AB-FUBINACA, was isolated from an herbal 
product sold in the markets as an incense product. The market is 
flooded with similar products marketed as scents or room odorizers. 
This clearly necessitates the urgent increase in international co-
operation between criminal evidences officials and legislators in order 
to combat this phenomenon. AB-FUBINCA has not yet been scheduled 
as a controlled substance in the state of Kuwait. 
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